Rhone-Poulenc's Giant Leap
Rhone-Poulenc Rorer's new Gencell division is a radical departure for this conservative French company as well as for the industry. Instead of trying to fit one of series of biotech bets into a large internal research structure, it is creating an organization devoted to in-licensing a broad range of technologically compatible probrams centered around gene therapy and cell therapy.
You may also be interested in...
Boston Scientific has agreed to pay $1.07bn to acquire Lumenis’ surgical laser business from Baring Private Equity Asia. See what Meghan Scanlon, president of Boston Scientific’s urology and pelvic health business, said about it here.
US Remains Conservative On Vaccine Dosing Regimens As CDC’s ACIP Highlights Minimal Comfort With Relying On Unproven Correlates
The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices concerns about making COVID-19 vaccine dose regimen changes based on unproven immune correlates of protection could be a warning sign to sponsors about roadblocks they might face if updating vaccines to address viral variants or conducting pediatric studies relying on such surrogate endpoints.
Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.